Search

Your search keyword '"Burger, Emily A."' showing total 283 results
Start Over Author "Burger, Emily A."
283 results on '"Burger, Emily A."'

6. Sociodemographic characteristics associated with cervical cancer screening participation by send‐to‐all and opt‐in HPV self‐sampling: Who benefits? Results from a randomized controlled trial among long‐term non‐attending women in Norway

Author

Hansen, Bo T., Nygård, Mari, Castle, Phil E., Burger, Emily A., and Aasbø, Gunvor

Subjects
EARLY detection of cancer, RANDOMIZED controlled trials, CERVICAL cancer, HUMAN papillomavirus, WOMEN'S employment
Abstract

With the objective to investigate associations between sociodemographic characteristics and participation in interventions designed to increase participation in cervical cancer screening among under‐screened women, we randomized a random sample of 6000 women in Norway aged 35–69 years who had not attended cervical screening for ≥10 years to receive either (i) a reminder to attend regular screening (control), (ii) an offer to order a self‐sampling kit (opt‐in), or (iii) a self‐sampling kit unsolicited (send‐to‐all). We analyzed how sociodemographic characteristics were associated with screening participation within and between screening arms. In the send‐to‐all arm, increased screening participation ranged from 17.1% (95% confidence interval [95% CI] = 10.3% to 23.8%) to 30.0% (95% CI = 21.5% to 38.6%) between sociodemographic groups. In the opt‐in arm, we observed smaller, and at times, non‐significant increases within the range 0.7% (95% CI = −5.8% to 7.3%) to 19.1% (95% CI = 11.6% to 26.7%). In send‐to‐all versus control comparisons, there was greater increase in participation for women in the workforce versus not (6.1%, 95% CI = 1.6% to 10.6%), with higher versus lower income (7.6%, 95% CI = 2.2% to 13.1%), and with university versus primary education (8.5%, 95% CI = 2.4% to 14.6%). In opt‐in versus control comparisons, there was greater increase in participation for women in the workforce versus not (4.6%, 95% CI = 0.7% to 8.5%), with higher versus lower income (6.3%, 95% CI = 1.5% to 11.1%), but lower increase for Eastern European versus Norwegian background (−12.7%, 95% CI = −19.7% to −5.7%). Self‐sampling increased cervical screening participation across all sociodemographic levels, but inequalities in participation should be considered when introducing self‐sampling, especially with the goal to reach long‐term non‐attending women. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Development and Calibration of a Mathematical Model of Anal Carcinogenesis for High-Risk HIV-Infected Men

Author

Burger, Emily A, Dyer, Michael A, Sy, Stephen, Palefsky, Joel M, de Pokomandy, Alexandra, Coutlee, François, Silverberg, Michael J, and Kim, Jane J

Subjects
Infectious Diseases, Prevention, Cancer, Sexually Transmitted Infections, HIV/AIDS, Clinical Research, Digestive Diseases, Aetiology, 2.2 Factors relating to the physical environment, 2.1 Biological and endogenous factors, Infection, Good Health and Well Being, Adult, Alphapapillomavirus, Anti-HIV Agents, Anus Neoplasms, CD4 Lymphocyte Count, Calibration, HIV Infections, Humans, Male, Middle Aged, Models, Statistical, Risk Factors, Tumor Virus Infections, HPV, anal neoplasms, decision analysis, mathematical model, Clinical Sciences, Public Health and Health Services, Virology
Abstract

OBJECTIVES:Men who have sex with men who are living with HIV are at highest risk for anal cancer. Our objective was to use empirical data to develop a comprehensive disease simulation model that reflects the most current understanding of anal carcinogenesis, which is uniquely positioned to evaluate future anal cancer screening strategies and provide insight on the unobservable course of the disease. SETTING:North America. METHODS:The individual-based simulation model was calibrated leveraging primary data from empirical studies, such as a longitudinal HIV-positive men who have sex with men cohort study [Human Immunodeficiency and Papilloma Virus Research Group (HIPVIRG); n = 247] and the North American AIDS Cohort Collaboration on Research and Design [(NA-ACCORD); n = 13,146]. We used the model to infer unobservable progression probabilities from high-grade precancer to invasive anal cancer by CD4 nadir and human papillomavirus (HPV) genotype. RESULTS:The calibrated model had good correspondence to data on genotype- and age-specific HPV prevalence; genotype frequency in precancer and cancer; and age- and nadir CD4-specific cancer incidence. The model-projected progression probabilities differed substantially by HPV genotype and nadir CD4 status. For example, among individuals with CD4 nadir

Published
2018

12. The Spillover Effects of Extending Liver Transplantation to Patients with Colorectal Liver Metastases: A Discrete Event Simulation Analysis.

Author

Sjule, Hanna Meidell, Vinter, Caroline N., Dueland, Svein, Line, Pål-Dag, Burger, Emily A., and Bjørnelv, Gudrun Marie Waaler

Abstract

Background: Liver transplantation is an alternative treatment for patients with nonresectable colorectal cancer liver-only metastases (CRLM); however, the potential effects on wait-list time and life expectancy to other patients on the transplant waiting list have not been considered. We explored the potential effects of expanding liver transplantation eligibility to include patients with CRLM on wait-list time and life expectancy in Norway. Methods: We developed a discrete event simulation model to reflect the Norwegian liver transplantation waiting list process and included 2 groups: 1) patients currently eligible for liver transplantation and 2) CRLM patients. Under 2 alternative CRLM-patient transplant eligibility criteria, we simulated 2 strategies: 1) inclusion of only currently eligible patients (CRLM patients received standard-of-care palliative chemotherapy) and 2) expanding waiting list eligibility to include CRLM patients under 2 eligibility criteria. Model outcomes included median waiting list time, life expectancy, and total life-years. Results: For every additional CRLM patient listed per year, the overall median wait-list time, initially 52 d, increased by 8% to 11%. Adding 2 additional CRLM patients under the most restrictive eligibility criteria increased the CRLM patients' average life expectancy by 10.64 y and decreased the average life expectancy for currently eligible patients by 0.05 y. Under these assumptions, there was a net gain of 149.61 life-years over a 10-y programmatic period, which continued to increase under scenarios of adding 10 CRLM patients to the wait-list. Health gains were lower under less restrictive CRLM eligibility criteria. For example, adding 4 additional CRLM patients under the less restrictive eligibility criteria increased the CRLM patients' average life expectancy by 5.64 y and decreased the average life expectancy for currently eligible patients by 0.12 y. Under these assumptions, there was a net gain of 96.36 life-years over a 10-y programmatic period, which continued to increase up to 7 CRLM patients. Conclusions: Our model-based analysis enabled the consideration of the potential effects of enlisting Norwegian CRLM patients for liver transplantation on wait-list time and life expectancy. Enlisting CRLM patients is expected to increase the total health effects, which supports the implementation of liver transplantation for CRLM patients in Norway. Highlights: Given the Norwegian donor liver availability, adding patients with nonresectable colorectal cancer liver-only metastases (CRLM) to the liver transplantation waiting list had an overall modest, but varying, impact on total waiting list time. Survival gains for selected CRLM patients treated with liver transplantation would likely outweigh the losses incurred to patients listed currently. To improve the total life-years gained in the population, Norway should consider expanding the treatment options for CRLM patients to include liver transplantation. Other countries may also have an opportunity to gain total life-years by extending the waiting list eligibility criteria; however, country-specific analyses are required. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Cost‐effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model‐based analysis.

Author

Portnoy, Allison, Pedersen, Kine, Sy, Stephen, Tropé, Ameli, Engesæter, Birgit, Kim, Jane J., and Burger, Emily A.

Subjects
HUMAN papillomavirus, COST effectiveness, MEDICAL triage, VACCINATION, WATCHFUL waiting
Abstract

As Norway considers revising triage approaches following their first adolescent cohort with human papillomavirus (HPV) vaccination entering the cervical cancer screening program, we analyzed the health impact and cost‐effectiveness of alternative primary HPV triage approaches for women initiating cervical cancer screening in 2023. We used a multimodeling approach that captured HPV transmission and cervical carcinogenesis to evaluate the health benefits, harms and cost‐effectiveness of alternative extended genotyping and age‐based triage strategies under five‐yearly primary HPV testing (including the status‐quo screening strategy in Norway) for women born in 1998 (ie, age 25 in 2023). We examined 35 strategies that varied alternative groupings of high‐risk HPV genotypes ("high‐risk" genotypes; "medium‐risk" genotypes or "intermediate‐risk" genotypes), number and types of HPV included in each group, management of HPV‐positive women to direct colposcopy or active surveillance, wait time for re‐testing and age at which the HPV triage algorithm switched from less to more intensive strategies. Given the range of benchmarks for severity‐specific cost‐effectiveness thresholds in Norway, we found that the preferred strategy for vaccinated women aged 25 years in 2023 involved an age‐based switch from a less to more intensive follow‐up algorithm at age 30 or 35 years with HPV‐16/18 genotypes in the "high‐risk" group. The two potentially cost‐effective strategies could reduce the number of colposcopies compared to current guidelines and simultaneously improve health benefits. Using age to guide primary HPV triage, paired with selective HPV genotype and follow‐up time for re‐testing, could improve both the cervical cancer program effectiveness and efficiency. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models

Author

Brisson, Marc, Bénard, Élodie, Drolet, Mélanie, Bogaards, Johannes A, Baussano, Iacopo, Vänskä, Simopekka, Jit, Mark, Boily, Marie-Claude, Smith, Megan A, Berkhof, Johannes, Canfell, Karen, Chesson, Harrell W, Burger, Emily A, Choi, Yoon H, De Blasio, Birgitte Freiesleben, De Vlas, Sake J, Guzzetta, Giorgio, Hontelez, Jan A C, Horn, Johannes, Jepsen, Martin R, Kim, Jane J, Lazzarato, Fulvio, Matthijsse, Suzette M, Mikolajczyk, Rafael, Pavelyev, Andrew, Pillsbury, Matthew, Shafer, Leigh Anne, Tully, Stephen P, Turner, Hugo C, Usher, Cara, and Walsh, Cathal

Published
2016
Full Text
View/download PDF

32. Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis

Author

Kim, Jane J., Simms, Kate T., Killen, James, Smith, Megan A., Burger, Emily A., Sy, Stephen, Regan, Catherine, and Canfell, Karen

Subjects
Medical care, Cost of -- Analysis, Papillomavirus infections -- Complications and side effects -- Prevention, Cervical cancer -- Risk factors -- Prevention, Adults -- Health aspects, Biological sciences
Abstract

Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was evaluated to inform national guidelines. Methods and findings We utilized 2 independent HPV microsimulation models to evaluate the cost-effectiveness of extending the upper age limit of HPV vaccination in women (from age 26 years) and men (from age 21 years) up to age 30, 35, 40, or 45 years. The models were empirically calibrated to reflect the burden of HPV and related cancers in the US population and used standardized inputs regarding historical and future vaccination uptake, vaccine efficacy, cervical cancer screening, and costs. Disease outcomes included cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers, as well as genital warts. Both models projected higher costs and greater health benefits as the upper age limit of HPV vaccination increased. Strategies of vaccinating females and males up to ages 30, 35, and 40 years were found to be less cost-effective than vaccinating up to age 45 years, which had an incremental cost-effectiveness ratio (ICER) greater than a commonly accepted upper threshold of $200,000 per quality-adjusted life year (QALY) gained. When including all HPV-related outcomes, the ICER for vaccinating up to age 45 years ranged from $315,700 to $440,600 per QALY gained. Assumptions regarding cervical screening compliance, vaccine costs, and the natural history of noncervical HPV-related cancers had major impacts on the cost-effectiveness of the vaccination strategies. Key limitations of the study were related to uncertainties in the data used to inform the models, including the timing of vaccine impact on noncervical cancers and vaccine efficacy at older ages. Conclusions Our results from 2 independent models suggest that HPV vaccination for adult women and men aged 30 to 45 years is unlikely to represent good value for money in the US., Author(s): Jane J. Kim 1,*, Kate T. Simms 2,3, James Killen 2, Megan A. Smith 2,3, Emily A. Burger 1,4, Stephen Sy 1, Catherine Regan 1, Karen Canfell 2,3 Introduction [...]

Published
2021
Full Text
View/download PDF

35. Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study

Author

Landy, Rebecca, primary, Haber, Gregory, additional, Graubard, Barry I, additional, Campos, Nicole G, additional, Sy, Stephen, additional, Kim, Jane J, additional, Burger, Emily A, additional, Cheung, Li C, additional, Katki, Hormuzd A, additional, Gillison, Maura L, additional, and Chaturvedi, Anil K, additional

Published
2023
Full Text
View/download PDF

39. A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions

Author

Burger, Emily A, primary, de Kok, Inge MCM, additional, O'Mahony, James F, additional, Rebolj, Matejka, additional, Jansen, Erik EL, additional, de Bondt, Daniel D, additional, Killen, James, additional, Hanley, Sharon J, additional, Castanon, Alejandra, additional, Regan, Mary Caroline, additional, Kim, Jane J, additional, Canfell, Karen, additional, and Smith, Megan A, additional

Published
2022
Full Text
View/download PDF

41. Author response: A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions

Author

Burger, Emily A, primary, de Kok, Inge MCM, additional, O'Mahony, James F, additional, Rebolj, Matejka, additional, Jansen, Erik EL, additional, de Bondt, Daniel D, additional, Killen, James, additional, Hanley, Sharon J, additional, Castanon, Alejandra, additional, Regan, Mary Caroline, additional, Kim, Jane J, additional, Canfell, Karen, additional, and Smith, Megan A, additional

Published
2022
Full Text
View/download PDF

43. Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting

Author

Burger, Emily A, Laprise, Jean-François, Sy, Stephen, Regan, Mary Caroline, Prem, Kiesha, Jit, Mark, Brisson, Marc, and Kim, Jane J

Abstract

We aimed to quantify the health impact of immediate introduction of a single-dose human papillomavirus (HPV) vaccination program in a high-burden setting, as waiting until forthcoming trials are completed to implement single-dose HPV vaccination may result in health losses, particularly for cohorts who would age-out of vaccination eligibility. Two mathematical models fitted to a high-burden setting projected cervical cancer incidence rates associated with (a) immediate implementation of one-dose HPV vaccination vs (b) waiting 5 years for evidence from randomized trials to determine if one- or two-doses should be implemented. We conducted analyses assuming a single dose was either noninferior or inferior to two doses. The models projected that immediate implementation of a noninferior single-dose vaccine led to a 7.2% to 9.6% increase in cancers averted between 2021 to 2120, compared to waiting 5 years. Health benefits remained greater with immediate implementation despite an inferior single-dose efficacy (80%), but revaccination of one-dose recipients became more important assuming vaccine waning. Under most circumstances, immediate vaccination avoided health losses for those aging out of vaccine eligibility, leading to greater health benefits than waiting for more information in 5 years.

Published
2022

44. Health impacts of COVID-19 disruptions to primary cervical screening by time since last screen: A model-based analysis for current and future disruptions

Author

Burger, Emily A., primary, de Kok, Inge M.C.M., additional, O’Mahony, James F, additional, Rebolj, Matejka, additional, Jansen, Erik E.L., additional, de Bondt, Daniel D., additional, Killen, James, additional, Hanley, Sharon J., additional, Castanon, Alejandra, additional, Kim, Jane J., additional, Canfell, Karen, additional, Smith, Megan A., additional, and Regan, Mary Caroline, additional

Published
2022
Full Text
View/download PDF

45. A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions

Author

Burger, Emily A., de Kok, Inge M.C.M., O'mahony, James F., Rebolj, Matejka, Jansen, Erik E.L., de Bondt, Daniel D., Killen, James, Hanley, Sharon J., Castanon, Alejandra, Regan, Mary Caroline, Kim, Jane J., Canfell, Karen, Smith, Megan A., Burger, Emily A., de Kok, Inge M.C.M., O'mahony, James F., Rebolj, Matejka, Jansen, Erik E.L., de Bondt, Daniel D., Killen, James, Hanley, Sharon J., Castanon, Alejandra, Regan, Mary Caroline, Kim, Jane J., Canfell, Karen, and Smith, Megan A.

Abstract

We evaluated how temporary disruptions to primary cervical cancer (CC) screening services may differentially impact women due to heterogeneity in their screening history and test modality. We used three CC models to project the short-and long-term health impacts assuming an underlying primary screening frequency (i.e., 1, 3, 5, or 10 yearly) under three alternative COVID-19-related screening disruption scenarios (i.e., 1-, 2-, or 5-year delay) versus no delay in the context of both cytology-based and human papillomavirus (HPV)-based screening. Models projected a relative increase in symptomatically detected cancer cases during a 1-year delay period that was 38% higher (Policy1-Cervix), 80% higher (Harvard), and 170% higher (MISCAN-Cervix) for underscreened women whose last cytology screen was 5 years prior to the disruption period compared with guidelines-compliant women (i.e., last screen 3 years prior to disruption). Over a woman’s lifetime, temporary COVID-19-related delays had less impact on lifetime risk of developing CC than screening frequency and test modality; however, CC risks increased disproportionately the longer time had elapsed since a woman’s last screen at the time of the disruption. Excess risks for a given delay period were generally lower for HPV-based screeners than for cytology-based screeners. Our independent models predicted that the main drivers of CC risk were screening frequency and screening modality, and the overall impact of disruptions from the pandemic on CC outcomes may be small. However, screening disruptions disproportionately affect underscreened women, underpinning the importance of reaching such women as a critical area of focus, regardless of temporary disruptions.

Published
2022

49. Veteran Adherence to Oral Versus Injectable Alcohol Use Disorder Medication Treatment

Author

Dorflinger, Charles, Carey, Heather, Roche, Jennifer, Burant, Christopher, LeHew, Colleen, Stewart, Hayden, Mitchell, Brian, Ayanga, Daniel, Walder, Annette, Cooler, Jordan, Wu, Shuwen, Frey, Theresa, Wenthur, Cody, Burk, Bradley, Ward, Alex, Clark, Brooke, Leung, Jonathan G, Kutzke, Jade, May, Heather P, Maehler, Colin, Kummer, Bethany, Hamner, Jennifer, Ariefdjohan, Merlin, Stutzman, Danielle L, Kicklighter, Jackson, Musco, Shaina, Singson, Grace Marielle, Pamintuan, Claire, Francisco, Janelle, Phan, Tam, Sevak, Rajkumar J, Rogan, Edward L, Kehoe, William A, Halliwell, Robert F, Kanter, Joel, Ryan, Holly, Patel, Krupa, Moukaddam, Nidal, Saunders, John, Fernandez, Luis, Shah, Asim, Wong, Jerry, Erowele, Goldina, Ruppelt, Sara, Tillery, Erika E, Baker, Joni, Loflin, Bobbi Jo, Gray, Emily, Conley, Giulia, Hembree, Amanda, Sterling, Jacyntha, Buige, Ashley N, Nguyen, Mimi, Harris, Suzanne C, Bhavsar, Nisha, Shah, Niti, Lee, Bona, Jeong, Seoyoung, Maroney, Megan E, Whalen, Eric D, Maloney, Rebecca M, Hagemeier, Nicholas E, Takamura, Kay, Rice, Amanda G, Furbish, Amelia B, Hebbard, Amy M, Ross, Clint, Cumbie, Holly, Hickey, J. Scott, Lalani, Falak, Mucha, Hannah, Saklad, Stephen R, Ma, Connie, Lee, Kelly, O’Donnell, Carolyn, Jackson, Sarah, Albee, Jennifer Nelson, Yapel, Ann, Nash, Cynthia, MacDonald, Danielle, King, Amelia, Schneiderhan, Mark, Hager, Keri, Bell Lynum, Karimah S, Nash, Abigail, Fu, Dong Jing, Ionescu, Dawn F, Sliwa, Jennifer Kern, Turkoz, Ibrahim, Dorson, Peter G, Canuso, Carla, Hsia, Stephanie, Nguyen, Julie, La, Amenda, Gruenberg, Katherine, MacDougall, Conan, Brockbank, Josh, Wong, Kara, Schultz, Erica, Pinchinat, Jessica, Thibeaux, Taylor M, McCants, Tamara, Lam, Jason, Diaz-Luna, Jose, Nguyen, Jennifer, Yokoyama, Melissa, Albiar, Olivia, Bradley, Bridget, Popish, Sarah J, Bounthavong, Mark, Lau, Marcos K, Wells, Daina L, Kay, Chad L, Harvey, Michael A, Himstreet, Julianne E, Christopher, Melissa L.D, Weeda, Erin R, McGraw, Daniel J, Gonzalez, Misty L, Pardo-Pfeiffer, Carlos, Rodeghiero, Abigail, Zhang, Lusi, Brown, Sarah Jane, Shan, Yuting, Lee, Adam M, Allen, Josiah D, Eum, Seenae, Bishop, Jeffrey R, Gonzalez, Rolando, Wahl, Kimberly, Naglich, Andrew, Ayson, Marl, Thomas, Kelan, Renfro, Mandy L, Loera, Lindsey J, Hill, Lucas G, Tirado, Carlos, Delerme, Dante, Dean, Taylor, Cullen, Marissa, Straley, Craig M, Carr, Chelsea N, Sun, Wendy, Alzouby, Hiba, Harris, Suzanne, Banker, Christopher M, Cook, Sarah F, Muir, Justin, Brodie, Daniel, Cremers, Serge, Bies, Robert R, Dzierba, Amy L, Moton, Robert, Saklad, Stephen, Ferris, Ryan E, Noble, Brie N, Hartung, Daniel M, Tjia, Jennifer, Furuno, Jon P, Ibrahim, Hajer, Duong, Dat, Malcolm, Benjamin, Gogineni, Hyma P, Zahn, Amy L, Alibeckoff, Chloe C, Connor, Sharon, Buranosky, Raquel, Livezey, Sabrina N, Daniell, Jessica, DeClercq, Josh, Choi, Leena, Zuckerman, Autumn, Shah, Nisha B, Kang, Ashley, Anksorus, Heidi, Troglin, Courtney G, Bouldin, J. Brooke, Schreiner, Shannon, McKinney, Mariah, Brown, Stacy D, Pond, Brooks B, Nguyen, Thu, Chin, Hyun Ji, Dambly, Nicolle, Augsten, Alberto, Themas, Samantha, Vicencio, Claudia, Horner, Caroline, Covert, Kelly, Lewis, Paul, Tharp, Jen, Sommi, Roger W, Bidollari, Ilda, Still, Daniel, Du, Yangchun, Yagoda, Sergey, Weiden, Peter J, Long, Katelyn, Vandiver, Emily, Johnson, Stephanie, Darazs, Brooks, Tillery, Erika, Silvia, Richard J, Lee, Kelly C, Bien, Ivy, Farahmand, Khodayar, Goldsmith, Hannah, Farrar, Mallory, Le, Hadley, Huynh, Quynh, Kim, Jane, McCausland, Kristen, Haider, Batool, White, Michelle K, O’Sullivan, Amy K, Rychlec, Kaitlin, Akerman, Sarah, Fratantonio, James, Saxon, Andrew, Thase, Michael E, Parikh, Sagar V, Maheshwari, Priya, Rothschild, Anthony J, Dunlop, Boadie W, DeBattista, Charles, Conway, Charles R, Forester, Brent P, Shelton, Richard C, Macaluso, Matthew, Brown, Krystal, Li, James, Jablonski, Michael R, Greden, John F, Gidal, Barry, Patsalos, Philip, Szaflarski, Jerzy, VanLandingham, Kevan, Critchley, David, Morrison, Gilmour, Weiss, Catherine, Meehan, Stine Rasmussen, Ouyang, John, Hobart, Mary, Rowe, William, Vanover, Kimberly E, Kane, John M, Satlin, Andrew, Durgam, Suresh, Davis, Robert E, Mates, Sharon, Correll, Christoph U, Tamminga, Carol, Rabon, Hannah, Smith, Jordan, Squires, Karrie, VanDaele, Madeline, Logan, Linda D, Zhang, Feng, DeSousa, Norberto J, Sallee, F. Randy, Lickrish, David, Incledon, Bev, Smith, Joseph L, Candon, Molly, Fadeyibi, Oluwatoyin, Connolly, K. Ryan, Lim, Suet, Neimark, Geoffrey, Mandell, David, Newcomer, John W, Silverman, Bernard, DiPetrillo, Lauren, Graham, Christine, Jiang, Ying, Simmons, Adam, Hopkinson, Craig, McDonnell, David, Kahn, Rene, King, Thomas R, Kando, Judith C, Pardo, Antonio, King, Thomas, Edwards, John B, Chen, Richard, Huo, Jason, Cutler, Andrew J, Fawver, Jay, Flanagan, Mindy, Smith, Thomas, Drouin, Michelle, Mirro, Michael, Yatham, Lakshmi N, Vieta, Eduard, McIntyre, Roger S, Jain, Rakesh, Earley, Willie R, Patel, Mehul, Brown, Lisa, Sehgal, Rahul, Yu, Ken, Al Habbab, Talal, Johnson, Holly, Dechairo, Bryan, Chen, Jack J, Singer, Carlos, Marder, Stephen R, Comella, Cynthia L, Shah, Chirag, Jimenez, Roland, Goodwin, Heather, Morrow, Gina, Tewksbury, Ashley, Waters, Kristin, Eggert, Robyn, Tallian, Kimberly, Sepulveda, Joe A, Rojas, Sarah, Sikand, Harminder, Sutera, Nathan, Iuppa, Courtney A, Nelson, Leigh Anne, Kriz, Carrie R, Burns, Nicole A, Lang, Shelby E, Elliott, Ellie S.R, Luong, Uyen, Elsobky, Teresa, Abelleira, Audrey, Awan, Sundus, Dume, Roberta, Dilich, Adam, Anderson, Mikaela, Park, Priscilla, Moehnke, Austin, Aebi, Cydreese, Feighner, Lydia, Vernon, Martein, Streit, Jessica, Kauer, Jill, Lemons, Amber, Diefenderfer, Lauren A, Moon, Joseph, Smith, Jordan O, Franck, Hugh A, Randle, C. Hope, Hedgepeth Kennedy, M. Lindsey, James, Shannon, Coplan, Benjamin, Ruekert, Laura, Puri, Shilpa, Yeleti, Ramya, Cathright, Sela, Coveart, Stephanie, Regen, Sloan, Stewart, Shannon, Stratton, Miranda, Haight, Robert, Hoeft, Dawn, Bishop, Danielle, De La Cruz, Austin, Aurelio, Mariellee, Prestenback, Autumn, Price, Paul L, Makuch, Christian X, Salisbury, Nicole M, Koch, Jessa, Palmer, Melissa C, Chace, Ashley, Price, Cristofer, Putney, Jessica, Khan, Fatima, Huntsman, Amanda, Hutcheson, Brooklyn, Hightower, Sharae, Ott, Carol A, Scott, Catherine, Balser, Amanda, Karas, Andrew, Hsu, Michael, Malin, Maureen, Robert, Sophie, Leung, Edwina, Mierzwa, Mark, Kay, Lehua, Bowling, Dalia, Allen, Sabrina, Weingartner, Melissa, Ventricelli, Daniel, Santa, Heather, Nowalk, Alexandra, Downs, George, Le, N, Mospan, C, Burton, Caitlin, Mathys, Monica, Gutierrez, Erika, Ali, Sarah, Chang, Joni, Holzum, Dorothy N, Griffith, June A, Morgan, Katherine T, Laguado, S. Andrea, Steavenson, Rosana, Mehvar, Mina, Bechtold, Carson L, Kim, Heesoo, Dopheide, Julie Ann, Anderson, Lindsey, Kleyn, Thomas, DiRenzo, Baely, Walroth, Todd, Adamczyk, Raechel, Kendrick, Jenna, Thomas, Christopher, Mailloux, Lindsay M, Haas, Matthew T, Larew, Janel M, Stohs, Matthew E, DeJongh, Beth M, Satow, Britney A, Titus-Lay, Erika, Clark, Suzanne, Dike, Dozie, Pinsonnault, John, Gamber, Joy, Roseberry, Samantha, Mitchell, Brian G, Nguyen, Mai, Willborn, Robert, Roche-Desilets, Jennifer, Dailey, Alison, Ignatowski, Michael, Routhieaux, Melanie, Kawsky, Jaclyn, Stratman, Jennifer, Corboy, Alexander, Norberte, Cherisse, Gross, Tonya, Daniel, Jeremy, Tran, Aaron N, Wary, Megan, Kostric, Anna, Schaller, Samantha, Shin, Yunjung, Maroney, Megan, Hampton, Chanese, Krieger, Kelly, Hartwig, Rachel, Thamawatanakul, Rani, Wilbur, Eileen, Shofner, Steven, Butler, Justin, Moody, Breanna, Davis, Elizabeth, Hofammann, Elizabeth, Liveoak, Katie, Mitchell, McKinley, Lebrecht, Morgan, Hawley, Joanne, Smigiel, Joe, Radtke, Michelle, Walkerly, Autumn, King, Morgan, Wakefield, Andrew, Downs, Mona, Hudson, Nancy, Burghart, Steven, Reynoldson, Jill, Booth, Macey, Ishino, Risa, Lee, Tammie, Wright, Melissa, Boggs, Angela, Kaur, Rajandeep, Patel, Parth, Smith, Thomas R, Theriault, Sarah, Okusaga, Olaoluwa, Reinstatler, Kristina, Hawk, David, Rush, Stephen, Vachuska, Michaela, Powell, Elizabeth, Lacro, Jonathan, Chehovich, Charisse, Demler, Tammie Lee, deRosas, Andrea, Trigoboff, Eileen, Taylor, Aminah, Singh, Divita, Burdge, Gary, Reynolds, Jamie, Kriz, Carrie, Burns, Nicole, Sommi, Roger, Yabs, Melanie, Sarpal, Deepak, Fabian, Tanya, Bartos, Lindsey, Tallman, Kristin, Johnson, Dara, Taylor, Daniel, Hogan, Brendon, Kwan, Peter, Bast, Aubree, Sanchez, Apolinar, Maglalang, Patricia D, Scheible, Mahli M, Skurat, McKenzie K, Jackson, Sarah K, Belknap, Jazmin N, Ostfeld, Larissa, Fahy, Megan, Nguyen, Tuyen, Bui, Hoa, Little, Meg M, Seifert, Randall, Maister, Ashley, McCarthy, Caitlin, Burger, Emily, Mullen, Sandy, Cusimano, Joseph, VandenBerg, Amy, Duquette, Meghan, Guttenberg, Viktoria, Matsunaga, Candace, White, Shelby, Richard, Andrea, Jones, Jessica, Morgan, Kaitlyn, Kelsey, Taylor, Sartin, Carrie J, Rickert, Leah, Ferrill, Laine, Vallabh, Anuja, Jhawar, Archana, Barrett, Monica, Ward, Sarah, Colvard, Michelle, Phan, Joann, Preinitz, Jennifer, Ellis, Marcus, Gibu, Matthew, Kivlehan, Audrey, Chiulli, Dana, Rhodes, Kirby, Brewer, T. Amber, Richard, Michelle, Kirwan, Brigit, Flowers, Gary, Albritton, Melinda, Sutton, Caroline M, McEachern, Sydney, Miskle, Benjamin, Barr, Rachel, Thomas, Chris, Yang, Waverly, Vogt, Caitlin, Charles, Amanda, Mathews, Alisha, Bhandari, Deepali, Olsen, Emily, Garling, Ashley, Liszka, Jessica, Goodman, Courtney S, Smith, Tammy, Barron, Ana, Williams, Andrew, Zuloaga, Andrea, Parra, Brianne, Miller, Joy, Blake, Jennifer, Toney, Gregory, Galeano, Kathleen, Morabito, Brianna, Smith, Sydney, Miller, Lindsey, Fleisch, Sheryl, Kim, Erika, Kurz, Troy, Peterson, Angela M, Gruca, Justin, McGuire, Michael, Stummer, Lauren, Yip, Agustin, Rodriguez-Villa, Fernando, Wilson, Jennifer, Sutton, Caroline, Owings, R. Laney, Herbst, Claire, Hosmer, Kane, Wulff-Burchfield, Elizabeth, Ramion, Shelby, Brown, Lauren, Shishko, Ilona, Allen, Sarah, Nichols, Taylor, Fawcett, Janet, Trent, Kelley N, Eatmon, Courtney V, Hershberger, Allie, Roads, Mary, Pittenger, Amy L, Dadebo, Victoria, Tomko, John R, Simeone, Danielle, Sherwood, Devon A, Morgan, Katherine, White, C. Whitney, Holzum, Dorothy, Adetunji, Oluwaseyi, Blalock, Meredith, Snyder, Sabrina Domicoli, Kneebusch, Jamie, Mitchell, Melissa, Butala, Niyati, McHugh, Trisha, McGuire, J Michael, Moller, Karen, Melton, Brittany, Mitchell, Melissa M, Chaplin, Kyrsten, Canto, Samantha, Hang Vu, Thi Thuy, Rey, Jose A, Elmaoued, Amre Adel, Hopper, Jessica, Do, Annette, Leckband, Susan G, Abraham, Dana L, Haught, Emma J, Kobulinsky, Lawrence R, Fabian, Tanya J, Greenwood, Jessica, Rey, Jose, Chen, Emily, Farhadian, Sanaz, Smith, Austin M, Hopkins, Tiffany M, Deardorff, O. Greg, Jenne, Victoria, Wood, Joshua, Trout, Megan, Beck, Niels C, Pals, Hale, Frazier, Erica, Cavaliere, Vincent S, DiPaula, Bethany A, Glassman, Matthew, Wehring, Heidi J, Mackowick, Marie, Park, Jaeboon, Love, Raymond C, Kelly, Deanna L, Newbold, Mervan, Fioravanti, Nicole, Brown, Matthew J, Casey, Emily R, Nadkarni, Neha, Oh, Sarah, Patel, Romi, Riedley, Taylor, Mathis, Erin, Fadden, Patrick, Madden, Cristina, Schneiderhan, Mark E, Hintsala, Madelynn, Stenehjem, David, Rufus, Krystal M, Elhakim, Athar, Zolezzi, Monica, Elamin, Waad M, Homs, Shorouk, Qubaiah, Iman K, Mahmoud, Doaa A, Tawfik, Enge M, Fritz, Merideth, Alman, Brianne, Wartman, Carolanne, Clark, Megan, Ott, Carol, Rainey, Carly A, Mann, Elise, Modany, Madison, Schoettmer, Amanda, Buckley, Tiffany, Patwardhan, Vidisha, Boyle, Cynthia J, Gardner, Kristen N, Hamby, Kerri, Ngo, Nichol, Kim, Lila Q, Chen, Steven W, Mosley, Scott, Dadiomov, David, Goldstone, Lisa W, DellaVecchia, Matthew J, Cauffield, Jacintha, Grim, Hannah, Eschler, Anna, Aladeen, Traci, Blondell, Richard, Capote, Horacio, Rainka, Michelle, Lee, Ashley, Shelley, Maria, Stoncius, Kristina, Berry, Jonathan, Doroudgar, Shadi, Johnson, Kayla, Pouliot, Jonathon, Rarrick, Christine, Hebbard, Amy, Shikwana, Sara, Koller, Katherine, Reed, Ellen, Hoefling, Austin D, Miles, Talia M, Ansara, Elayne D, Titova, Viktoriya, Kandela, Dalea, Douglass, Amber R, Ehrhard, Kimberly, Stanley, Madison, Ganihong, Carissa, Liu, Mei T, Bohnenberger, Kristin, Zuber, Nicole, Plunkett, McKenzie, Axelrod, Chelsey, Lightfoot, Myaa, Moore, Miranda, Crouse, Ericka, Olazo, Muriel, Taormina, Stephanie, Reiss, Rebecca, Denno, Nora, Johnson, Braniesha, Wilkening, Gwendolyn Lucy, Andrews, Haley, Neumeister, Kristen, Murad, Muhammad Ubaidullah, Reid, Bailey, Franco, Ashley, Stutzman, Danielle, Jorgensen, Jennifer, Basit, Saadia, Jensen, Aimee, Nadal, Celeste N, Truong, Quynh-Nhu, Jameson, Melanie, Knox, Erin D, Bota, Robert G, Wieruszewski, Patrick M, and Leung, Sarah B

Subjects
CPNP Foundation Strategic Goals Award Finalists, Therapeutic Case Report Abstracts, Original Research Abstracts, Therapeutic Case Report Award Finalists, Article, Encore Presentation Abstracts, Work in Progress Abstracts, Neuropsychology and Physiological Psychology, Original Research Award Finalists, Research Trainee Award Finalists, Pharmacology (medical), Neurology (clinical), General Pharmacology, Toxicology and Pharmaceutics, Innovative Practices Abstracts, Innovative Practices Award Finalists, Scientific Posters
Published
2020

50. sj-docx-1-mpp-10.1177_23814683211071093 ��� Supplemental material for Impact of Delaying Effective and Cost-Effective Policy Decisions: An Example From Cervical Cancer Prevention in Norway

Author

Portnoy, Allison, Nyg��rd, Mari, Trogstad, Lill, Kim, Jane J., and Burger, Emily A.

Subjects
111799 Public Health and Health Services not elsewhere classified, FOS: Health sciences
Abstract

Supplemental material, sj-docx-1-mpp-10.1177_23814683211071093 for Impact of Delaying Effective and Cost-Effective Policy Decisions: An Example From Cervical Cancer Prevention in Norway by Allison Portnoy, Mari Nyg��rd, Lill Trogstad, Jane J. Kim and Emily A. Burger in MDM Policy & Practice

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results